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Abstract
The aim of the present Monte Carlo study is to evaluate the variation of energy de-
position in healthy tissues in the human eye which is irradiated by brachytherapy sources
in comparison with the resultant dose increase in the gold nanoparticle(GNP)-loaded
choroidal melanoma. The effects of these nanoparticles on normal tissues are compared
between 103Pd and 125I as two ophthalmic brachytherapy sources. Dose distribution in the
tumor and healthy tissues have been taken into account for both mentioned brachyther-
apy sources. Also, in a certain point of the eye, the ratio of the absorbed dose by the
normal tissue in the presence of GNPs to the absorbed dose by the same point in the
absence of GNPs has been calculated. In addition, differences observed in the comparison
of simple water phantom and actual simulated human eye in presence of GNPs are also a
matter of interest that have been considered in the present work. The results show that
the calculated dose enhancement factor in the tumor for 125I is higher than that of the
103Pd. The difference between the eye globe and the water phantom is more obvious for
125I than that of the 103Pd when the ophthalmic dosimetry is done in the presence of
GNPs. Whenever these nanoparticles are utilized in enhancing the absorbed dose by the
eye tumor, the use of 125I brachytherapy source will greatly amplify the amount of dose
enhancement factor (DEF) in the tumor site without inflicting much damage to healthy
organs, when compared to the 103Pd source. Furthermore in Monte-Carlo studies of eye
brachytherapy, more precise definition of the eye phantom instead of a water phantom will
become increasingly important when we use 125I as opposed to when 103Pd is considered.
Keywords: Brachytherapy, Choroidal Melanoma, MCNP5, Gold nanoparticles, 103Pd
and 125I
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I Introduction
Uveal Melanoma is one of the primary ocular cancerous tumors which arises within the eye-
ball in the Uvea involving the Iris, Ciliary body or Choroid. In the majority of cases, ocular
melanoma develops slowly from the pigmented cells of the choroid which are named choroidal
melanoma. Although this kind of cancer is rare, it is the most common eye cancer in people
who are middle-aged or older [1–4].
Regarding the size and location of the tumor and also the rate of its progress, treatment of
the choroidal melanoma is managed. Enucleation, local resection and radiotherapy are the
most common therapeutic processes for the treatment of choroidal melanoma [5–7].
Radiotherapy itself, depending on the source location, has two main classifications frequently
regarded as internal and external source therapy. Brachytherapy, which is one of the most
widely applied forms of treatment, belongs to the former treatment plan. From its initial
appearance in the year 1930, brachytherapy, by the application of eye plaques, has played
an indispensable role in treating patients suffering from various eye tumors in all around the
world [8,9]. These plaques mainly function through conventional radionuclides such as 60Co,
106Ru, 125I, 103Pd, 90Sr and 131Cs [10]. Admittedly, many state of the art plaques carry
within themselves seeds of low-energy photon sources, while others merely operate as solid
beta emitters [11].
Considering the sensitive tissues which the eye is involved in, ocular tumors present a thera-
peutic challenge [12]. Although the radiation is effective therapeutically, it can be harmful to
healthy tissues. Plaque brachytherapy is the most widely used treatment which aims to trans-
fer the maximum amount of dose to the tumor, while preventing dose absorption by normal
tissue [13,14]. However, in the period of treatment, both the tumor and the proximal normal
tissues obey a certain pattern in radiation absorption; hence, in this therapeutic procedure,
minimizing the absorbed dose by the normal tissue is still one of the major concerns.
Applying the gold nanoparticles (GNPs) as radiation dose enhancer in combination with
brachytherapy can be an effective method to reduce the radiation effects on healthy nearby
tissues.
In the in-vivo study by Hainfeld et al., on the use of GNPs in mice which were irradiated
by X-ray photons, the results show that the presence of GNPs in the tumor will cause more
radiation dose in the cancerous cells than that of in the healthy tissues [15,16].
In the in-vitro study by T. Kong et al., on the application of GNPs to enhance radiation
cytotoxicity, the results show that radiotherapy killed more cancerous cells in the presence
of GNPs than that of in the absence of these nanoparticles [17]. Subsequently, GNPs ra-
diosensitization has been observed in more controlled in-vitro irradiation of cells and plasmid
DNA [18–20].
The idea of using gold nanoparticles in cancer therapy as a radio-sensitizer is not a new one
and several Monte Carlo, in-vitro and in-vivo studies on the application of nanotechnology-
based cancer therapy have been performed using GNPs [21–24]. However, only a handful of
studies such as [25] have yet been conducted to investigate the effects of these nanoparticles
on human eye tumors such as choroidal melanoma.
If the choroidal melanoma tumor could be loaded with these nanoparticles in proper concen-
trations and dimensions, this would lead to a higher absorbed dose by the tumor during a
shorter time. Due to the fact that the eye is an extremely sensitive organ, the reduction of the
period of treatment would decrease the absorbed dose by normal cells, resulting in a major
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cut down in the damage inflicted upon the mentioned organ.
Regarding the radio-sensitizing properties of gold nanoparticles, dose enhancement in the
tumor is expected when the GNPs-loaded choroidal melanoma is locally irradiated with
brachytherapy sources. However, considering the healthy tissues, and due to different seed
models which are used in the eye plaque therapy, the variation of energy deposition in nor-
mal tissues, in comparison with the resultant dose increase in the tumor by diverse sources
is of outmost importance in the investigation of GNPs effects on ophthalmic brachytherapy
dosimetry.
Some studies have been carried out through making a dosimetry comparison between 103Pd
and 125I [3, 11]. These studies reported higher absorbed dose by the tumor for 103Pd versus
125I for an equivalent radiation time. However, the focus of the present study is to know what
changes will occur in absorbed dose by the healthy tissues compared to the dose increase in
the tumor when the nanoparticles-induced tumor is irradiated with 125I and 103Pd.
Here, in addition to providing a rigorous comparison between 103Pd and 125I low-energy
photon sources within COMS eye plaques in the study of the effects of GNPs in ophthalmic
brachytherapy, once again, we also studied the difference between water phantom and human
eye globe in the presence and absence of these nanoparticles for both mentioned sources. The
mean absorbed dose to the apex of the tumor as well as other critical points in both water
and eye phantoms were calculated in order to evaluate the effects of both sources and identify
the most efficient source with the least amount of induced cell damage to critical points and
healthy tissue in the presence of GNPs.
To this end the eye globe was simulated following the way of previous work [25] precisely by
considering different parts of the eye and their components. Here, both water and eye phan-
toms were simulated with MCNP5 code in which the water and eye phantoms were nearly
identical, owing to the fact of water being taken as the composition of the simulated eye globe,
albeit by considering accurate geometry of the noted organ. The geometric characteristic of
this phantom is in accordance with the eye of an adult. A certain diameter of 50 nm was
chosen for GNPs which has been shown to be the optimal size to achieve maximal uptake in
mammalian cells [26]. Dosimetric characteristics of a single source for 125I and 103Pd were
utilized to validate the accuracy of the Monte-Carlo simulation technique. Fully-loaded 16mm
COMS standard eye-plaque with 125I source model 6711 (GE Healthcare/Oncura) and also
103Pd source model 200 (Theraseed) were the focus of this study.
II Material and Methods
The primary goal of this work is to examine and compare the efficiency of the use of oph-
thalmic brachytherapy in combination with GNPs in the treatment of ocular tumor between
125I and 103Pd sources.
The present Monte Carlo simulations are carried out using MCNP5 code [27]. The mentioned
code benefits from a three-dimensional heterogenous geometry for both photons and electrons
situated within the energy range of 1 KeV to 1 GeV; moreover, the libraries incorporated
within MCNP5 are based upon the 8th release of ENDF/B-VI [28]. *F8 tally following 109
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histories and F6 tally following 107 histories were used in this study to perform the phantom
dosimetry and the air kerma simulations respectively, in order to achieve a relative statistical
error of less than 1% .
The current Monte-Carlo study was conducted with two phantom test cases (water phantom
and complete simulated human eye) in which, the ophthalmic brachytherapy dosimetry was
evaluated in both cases, in the presence and the absence of gold nanoparticles using the full
loaded eye plaque containing 125I and 103Pd sources. We simulated the human eye globe in
a manner similar as indicated in our previous work [25].
In order to define complete human eye globe, its components have been simulated using in-
terface among different shapes with specific geometry and characteristics. The exact method
of simulation of the eye globe and the tumor has been thoroughly explained in the previous
report [25]; hence, all the details relating to the simulated phantoms are based upon the men-
tioned report; furthermore, in addition to the 16mm COMS eye plaque loaded with 13 125I
seeds, a 16mm eye plaque containing 13 103Pd seeds with the exact same coordinates were
defined. The center of the simulated eye globe coincided with the origin.
Rows of cubic voxels, with individual volumes of 0.05cm3 , were utilized to evaluate the depth
dose of the 125I and 103Pd radionuclide sources within both water and eye phantoms. The
mentioned voxels were assumed to be arranged on the central axis of the eye plaque, which has
been described in previous study [25]. According to the work done in the previous study [25],
an equator temporal eye Melanoma with a height of 0.5cm is considered. The COMS-style
eye plaque with the diameter of 16mm was modeled on the equator temporal periphery to the
eyeball.
It is a scientifically proven fact that the optimum GNPs uptake within cancerous cells occurs
when the noted substances are roughly 50nm in diameter [26]; hence, the study benefits from
the deployment of 50nm GNPs within the tumor with varying concentrations of 7mg, 10mg,
18mg, 30mg. Given the noted facts, the tumor is latticed by identical cubes, each with a
volume of 0.1cm3.
The dose enhancement factor(DEF) has been calculated to compare the effects of the presence
of GNPs in brachytherapy for the noted configurations of sources and phantoms. DEF is the
ratio of the absorbed dose by the tumor which is loaded with GNPs to the absorbed dose
by the tumor with out these nanoparticles. Also, the dose distribution in different points
of the eye has been determined for two mention sources in both eye and water phantoms.
validity of dosimetry computations for both the simulated sources were investigated by pa-
rameterized calculations such as Air Kerma Strength, Dose Rate Constant, and Radial Dose
Function(RDF), which were then compared with the reported results of Thomson et al and
Rivard et al [29, 30]. For RDF calculations, in accordance with previous studies [25], each of
the brachytherapy sources were simulated within a water phantom, 30cm3 in volume; further-
more, for the calculations related to Dose Fall-Off, tori cells with radial distances of 0.5cm to
10cm were simulated.
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III Results
A Calculations of TG-43 parameter
The TG-43 dosimetry parameter (Air Kerma Strength, Dose rate constant and RDF) have
been calculated for 103Pd following the approach of the previous work [25]. The calculated
RDF in the present work, those reported by Thomson et al [29] and TG-43 [30] have been
shown in Table1 and Fig.1 . Also, the calculated dose rate constant in this work, those
reported by Thomson et al and TG-43 have been shown in Table2. The results show excel-
lent agreement between them. It is also noteworthy to mention that all the referred TG-43
parameter dosimetry were calculated for 125I in the previous work [25].
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Figure 1: The calculated Radial dose function for 103Pd source. The relative statistical
uncertainties is less than 1%. The size of voxeles which the dose was scored in are the same
as the previous work [25].
B Dosimetry Calculations
Fig.2 shows the depth dose curve in the plaque central axis direction for 103Pd source in the
fully-loaded 16mm COMS eye plaque in water phantom where the dose is presented relative
to the dose at the tumor apex. The calculations have been done by *F8 tally. The results
have been compared with those reported by Thomson et al [29] with an excellent agrement
between them.
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Figure 2: The ratio of plaque central axes to the dose at the tumor apex for 103Pd in the
water phantom. The results have been compared with Thomson et al [29].
The dose to points of interest has been calculated in the water phantom and eye globe for
both 125I and 103Pd sources and the results have been reported in Table3. Having yielded a
relative statistical uncertainty is less than 1%, with the maximum percentage being apparent
in the opposite side of the eye, and the minimal amount of the noted factor observable in the
sclera, the study has tabulated the full body of prescription points within the aforementioned
Table3.
The dose enhancement factor (DEF) has been calculated for both 125I and 103Pd sources.
This calculation has been done for different concentration of GNPs within the water phantom
and compared with the calculated DEF for 125I in Fig.3.
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Figure 3: The calculated (DEF) for 50nm GNPs within the tumor with concentrations of(7,
10, 18 and 30mg)/(g of tumor). The calculation have been done in the water phantom with
fully-loaded 16mm COMS eye plaque of 125I and 103Pd sources.
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A comparison between water phantom and eye globe in calculation of dose enhancement fac-
tor for 103Pd is shown in Fig.4. The tally cells have been placed along the central axis of the
plaque, starting from the sclera near the plaque to the sclera opposite side of the plaque.
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Figure 4: The calculated (DEF) for 50nm GNPs within the tumor with concentrations of(7,
10, 18 and 30mg)/(g of tumor) in the eye and water phantoms for 103Pd source.
IV Discussion
Regarding the radiation enhancement properties of GNPs, studies have indicated that in ra-
diotherapy of cancerous cells, the presence of these nanoparticles in the tumor site will locally
increase the absorbed dose. Delivering the required dose in a shorter period of time will
ultimately result in reduced time of radiation exposure, which in turn would diminish the
delivered dose to the normal tissues.
In the previous study [25], the dose enhancement properties of GNPs on Choroidal Melanoma
for 125I source were investigated. Given the differences in the properties of ophthalmic
brachytherapy sources, the effects of the presence of GNPs in the tumor site in minimiz-
ing the damage done to normal tissue for each of these sources can be further investigated
and compared.
The results of this study have been quick to point out that, in brachytherapy of Choroidal
Melanoma, the 125I source has granted us a greater DEF in the presence of GNPs when
compared with the 103Pd source. As it is pointed out in Fig.3, the resultant DEF in the
apex of the tumor for GNPs concentrations of 30, 18, 10 and 7 mg/g are equal to 4.91, 3.37,
2.32, 1.94 respectively for 125I source , while are 3.66, 2.63, 1.91 and 1.62 respectively for
the 103Pd source. The apparent deviances for the mentioned sources are greater for higher
concentration.
It is also noteworthy to mention that, the dosimetry calculations for the eye in the presence
of GNPs report no eye-catching differences for the absorbed dose in the healthy tissue in
comparison with the case where GNPs were absent for each of the noted sources. In reference
to the noted evidence, in brachytherapy of eye Melanoma in presence of GNPs, it is more
efficient to utilize the 125I source, for it grants a higher DEF when compared with the 103Pd
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source.
The importance of defining an actual eye phantom instead of the water phantom in Monte
Carlo studies has been another factor gaining much attention in the recent years. The results
of Fig.4 signify that calculations of the resultant DEF in the tumor for the brachytherapy of
eye Melanoma utilizing a 103Pd source show no striking difference when the actual eye model
and the water phantom are compared. This is while according to the previous study [25],
the results pointed out that the use of the actual eye phantom in the Monte-Carlo study of
the dosimetry in eye Melanoma, with 125I source, whilst GNPs were present, was of utmost
importance.
Furthermore, the results obtained from Table3 indicate that in a healthy tissue such as the
lens, the the difference in the calculated absorbed dose, between water and eye phantoms, in
varying concentrations of GNPs, is around 19% for the 125I source, and 14% for the 103Pd
source. As stated previously, the deviances for both phantoms, in the presence of GNPs are
greater when compared to those that were in the absence of the mentioned substance.
As it is apparent from Table3, the calculated difference in the DEF at the apex of the tumor,
between water and eye phantoms for the 125I source is roughly 4%, while the noted deviance
is about 2% for the 103Pd source.
All in all, regarding the numerous sources that are employed in the radiotherapy of the eye
Melanoma, the possible effects of these sources, whilst accompanied by GNPs, in altering the
period of treatment, is a matter of heated debate, and requires more comprehensive investi-
gations.
V Conclusion
The present study indicates that the presence of GNPs as a method of dose enhancement in
treatment of eye tumors grants a higher DEF for the 125I brachytherapy source as opposed
to that of the 103Pd source.
Previous studies have been quick to point out that, in the period of brachytherapy treatment
of the eye(in the absence of GNPs) the 103Pd source generates a greater dose in the tumor site.
Since the results designate that the difference between the absorbed dose in normal tissue, in
the presence of GNPs, is negligible when the two sources are compared, it is safe to say that
the use of the 125I source along with GNPs would yield a higher DEF in the tumor site of the
eye Melanoma.
The previous study has also specified that ever-more accurate definition of the actual eye
phantom, instead of the water phantom, is an absolute necessity for precise dosimetry of
the eye Melanoma when examination utilizing the 125I source is intended. However, even
with the aforementioned facts, the dosimetry results obtained for the 103Pd source in both
the water and eye phantoms are roughly similar; thus, in brachytherapy studies of the eye
involving Monte-Carlo methods, designation of a water phantom as an alternative for the eye
phantom breeds no observable difference in the results, and efficiently replicates those of the
eye phantom.
8
VI Tables
Table 1: A comparison between the simulated (RDF) of 103Pd source in this work with the
published data by other investigators.
Radial Dose Function, g(r )
Distance from source(cm) This work Thomson et al [29] TG-43 [30]
0.05 0.25067 0.249 —
0.06 0.41397 0.401 —
0.07 0.57996 0.561 —
0.08 0.73469 0.704 —
0.09 0.86419 0.826 —
0.1 0.96223 0.929 0.911
0.15 1.26322 1.226 1.21
0.2 1.36332 1.34 —
0.25 1.38322 1.381 1.37
0.3 1.38156 1.39 1.38
0.4 1.33207 1.365 1.36
0.5 1.29172 1.31 1.3
0.6 1.21264 1.245 —
0.7 1.18272 1.18 —
0.75 1.14951 1.148 1.15
0.8 1.10612 1.113 —
0.9 1.04254 1.059 —
1 1.00059 1.001 1
1.5 0.76306 0.742 0.749
2 0.57565 0.552 0.555
2.5 0.42646 0.407 0.41
3 0.31547 0.298 0.302
3.5 0.23145 0.219 0.223
4 0.16997 0.16 0.163
4.5 0.12385 0.117 —
5 0.09241 0.0865 0.0887
5.5 0.06699 0.0635 —
6 0.05031 0.0469 0.0482
6.5 0.03689 0.0346 —
7 0.02696 0.0256 0.0262
7.5 0.02069 0.0193 —
8 0.01552 0.0147 —
8.5 0.01175 0.0112 —
9 0.00893 0.0084 —
9.5 0.00703 0.0064 —
10 0.00523 0.0051 0.00615
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Table 2: A comparison of the dose rate constant of 103Pd brachytherapy source in water,
simulated in this project with the published data.
Thomson et al [29] M.J. Rivard et al [30] This work
Dose rate constant 0.772 0.686 0.69± 0.01
Table 3: A comparison of the dose (unit of (Gy/per particle) ×10−15) to the critical points
of the eye in the water and eye phantoms for both fully-loaded 16mm (13-seeds) COMS
standard 125I and 103Pd eye plaques. Eye refers to the eye phantom and water refers to the
water phantom in which the eye phantom was filled of water. “ 7mg/g, 10mg/g, 18mg/g and
30mg/g” refer to the concentration of GNPs inside the tumor.
Water
125I 103Pd 7mg/g 7mg/g 10mg/g 10mg/g 18mg/g 18mg/g 30mg/g 30mg/g
Location (125I) (103Pd) (125I) (103Pd) (125I) (103Pd) (125I) (103Pd)
Sclera 138.97 217.97 165.45 241.12 165.56 241.00 165.86 235.10 166.16 235.86
apex 41.03 64.31 79.78 104.18 95.22 123.00 138.29 169.24 201.48 235.67
Center of eye 13.85 19.28 14.09 16.86 14.01 16.80 14.01 16.78 14.10 16.76
Opposite side 2.91 2.62 3.22 2.12 3.20 2.13 3.20 2.37 3.24 2.48
Optic nerve 4.99 5.05 5.07 4.59 5.07 4.59 5.07 4.74 5.08 4.93
Lens 9.54 11.92 10.72 11.41 10.77 11.40 10.77 11.34 10.73 11.39
Macula 6.97 7.68 7.72 7.48 7.71 7.48 7.71 7.52 7.77 7.47
eye
125I 103Pd 7mg/g 7mg/g 10mg/g 10mg/g 18mg/g 18mg/g 30mg/g 30mg/g
Location (125I) (103Pd) (125I) (103Pd) (125I) (103Pd) (125I) (103Pd)
Sclera 174.89 263.62 184.90 265.00 185.18 259.47 185.53 265.26 185.81 265.95
apex 43.12 64.37 80.50 105.00 96.21 122.39 138.46 173.59 200.69 241.61
Center of eye 14.76 18.82 13.46 16.20 13.48 16.25 13.47 16.67 13.53 16.66
Opposite side 3.75 2.89 3.41 2.41 3.39 2.95 3.39 2.69 3.38 2.69
Optic nerve 4.81 4.95 4.96 4.42 4.97 4.48 4.97 4.60 4.96 4.59
Lens 8.55 10.23 8.74 9.71 8.65 9.71 8.65 9.73 8.62 9.73
Macula 7.14 7.24 7.61 7.11 7.64 7.39 7.64 7.41 7.65 7.40
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